TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03798886

Intervention type: OTHER
Intervention: modified natural cycle
Description: we will use that drug in the natural modified transfer group after embryo transfer

Intervention type: OTHER
Intervention: modified natural cycle
Description: we will use that drug in the natural modified transfer group after embryo transfer

Intervention type: OTHER
Intervention: embryo transfer
Description: we will do transfer when the endometrium is ready

Intervention type: OTHER
Intervention: embryo transfer
Description: we will do transfer when the endometrium is ready
Study: NCT02118792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2728 Topical Ointment, 2%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching vehicle control
Study: NCT01113203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Progressive high intensity resistance training performed twice a week for 16 weeks, and achieving in 7 exercises for the main muscles, the protocol of 4 sets of 6RM and 2 of 4RM.
Study: NCT02908880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MANTA vascular closure device
Description: The appropriate size of MANTA closure device will be selected and used for the closure of femoral arterial access sites following the use of 10-14F devices or sheaths or the use of 15-18F devices or sheaths.
Study: NCT01681329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Description: Cognitive-behavioral therapy addressing intolerance of uncertainty, positive beliefs about worry, negative problem orientation, and cognitive avoidance

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral therapy
Description: Cognitive-behavioral therapy addressing intolerance of uncertainty, positive beliefs about worry, negative problem orientation, and cognitive avoidance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interpretation training
Description: Computerized interpretation training using Word-Sentence Association Paradigm
Study: NCT01758536

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Huatuo Zaizao Pills
Description: A tens of herbs botanical drug product 12 gram (g) in 72 mini pills formulation. It is to be used as 12 g each time, twice daily.
Study: NCT02657135

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive/Neuropsychological Testing
Description: These tests will be used to determine how the participant will continue with future procedures, and depending on results, may involve the participant returning to complete subsequent testing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular/Ocular-Motor Testing
Description: These assessments will involve a series of tests and questionnaires that focus on physical symptoms of TBI and will include dizziness, balance, ocular-motor coordination, and reflexes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical (Neck) Evaluation
Description: These assessments will involve a series of tests and questionnaires that focus on physical symptoms of TBI including neck mobility and pain levels.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep Evaluation
Description: These evaluations will focus on assessing insomnia (duration, frequency, daytime consequences), combat exposure, and the presence and severity of trauma history.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HDFT MRI
Description: This MRI aims at providing qualitative and quantitative assessments of the nature, location, and extent of white matter injury.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MR Spectroscopy (MRS)
Description: This is a noninvasive diagnostic test for measuring biochemical changes in the brain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MEG (Magnetoencephalography)
Description: This is a non-invasive neurophysiological technique that measures the magnetic fields generated by neuronal activity of the brain.
Study: NCT03931278

Intervention type: OTHER
Group type: OTHER
Intervention: learning and recall of a sequence of body movements
Description: The objective of this study to investigate, if learning and recall of a sequence of body movements (steps that realize a pattern on the ground) can be improved by self-produced music (having particular melodic-structures in relation to the pattern), compared to the same sound (a single tone) for each pattern in persons

Intervention type: OTHER
Group type: OTHER
Intervention: learning and recall of a sequence of body movements
Description: The objective of this study to investigate, if learning and recall of a sequence of body movements (steps that realize a pattern on the ground) can be improved by self-produced music (having particular melodic-structures in relation to the pattern), compared to the same sound (a single tone) for each pattern in persons
Study: NCT03335085

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00662844

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vitamin D3
Description: Oral, one capsule daily of vitamin D3 (400IU, 800IU, 1600 IU, or 2400IU) plus calcium citrate (1-4 tablets) twice daily to reach a total calcium intake of 1000-1200 mg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vitamin D3
Description: Oral, one capsule daily of vitamin D3 (400IU, 800IU, 1600 IU, or 2400IU) plus calcium citrate (1-4 tablets) twice daily to reach a total calcium intake of 1000-1200 mg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vitamin D3
Description: Oral, one capsule daily of vitamin D3 (400IU, 800IU, 1600 IU, or 2400IU) plus calcium citrate (1-4 tablets) twice daily to reach a total calcium intake of 1000-1200 mg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vitamin D3
Description: Oral, one capsule daily of vitamin D3 (400IU, 800IU, 1600 IU, or 2400IU) plus calcium citrate (1-4 tablets) twice daily to reach a total calcium intake of 1000-1200 mg/day
Study: NCT03630770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium-Chain Triglyceride (MCT) Oil
Description: Infants receive 0.5 ml/oz of MCT oil to their prescribed feedings for 21 days or until hospital discharge.
Study: NCT01809587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IQP-PO-101
Study: NCT00662844

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vitamin D3
Description: Oral, one capsule daily of vitamin D3 (400IU, 800IU, 1600 IU, or 2400IU) plus calcium citrate (1-4 tablets) twice daily to reach a total calcium intake of 1000-1200 mg/day
Study: NCT00250510

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulated insurance reimbursement
Description: Participants were told they would have the possibility of being reimbursed 50% ($150) of their initial fee ($300) if they: 1) paid the fee in advance or committed 3 monthly payments in advance, 2) attended 10 of 12 class sessions, and 3) lost at least 6% of their current body weight during the program.
Study: NCT03380910

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacy and Behavioral Health Team
Description: An interdisciplinary approach using medications through pharmacy support and counseling through behavioral health team members will be used to improve smoking cessation rates.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Motivational Interviewing
Description: Patients not ready to quit will be offered motivational interviewing to increase readiness to quit.
Study: NCT02350803

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mini plate
Description: in the intervention group, 4 L shaped titanium mini plates with 16 screws were fixed immediately after distraction phase and removal of distraction ossteogenesis to prevent the relapse after distraction
Study: NCT03204123

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ga-HBED-iPSMA PET
Description: Patients will be injected with 100-300 MBq of 68Ga-HBED-iPSMA and after a waiting of 60-90 minutes patients will be scanned from mid-skull to mid-thigh.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ga-HBED-iPSMA PET
Description: Patients will be injected with 100-300 MBq of 68Ga-HBED-iPSMA and after a waiting of 60-90 minutes patients will be scanned from mid-skull to mid-thigh.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: PET/CT
Description: PET/CT will be acquired using a GE 710 or 690 time-of-flight PET/CT scanner. Following a waiting period of 60-90 minutes post 68Ga-HBED-iPSMA administration, patients will be scanned from top of the skull to mid-thigh. Images will be acquired with patients in a supine position with their arms raised above their head. If patients cannot raise their arms above the head, the arms will be comfortably positioned and secured by the side of the patient. The PET may be combined with a CT scan as a PET/CT or a MRI scan as PET/MR.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Patients may undergo a diagnostic MRI of the prostate, other body parts or a whole-body MRI at the same imaging session as clinically indicated.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Patients may undergo a diagnostic MRI of the prostate, other body parts or a whole-body MRI at the same imaging session as clinically indicated.
Study: NCT04010669

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatostatin
Description: 2 amp of somatostatin at 1000ml normal saline solution in continuous 24-hour infusion for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 24 hours infusion of 1000ml Normal Saline solution 0.9%
Study: NCT00167635

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive-behavioral
Description: Cognitive-behavioral over 9 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive-behavioral
Description: Cognitive-behavioral over 9 weeks

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: cognitive-behavioral
Description: Cognitive-behavioral over 9 weeks
Study: NCT03196128

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digital communication
Description: Communicating with patients via email and text message.
Study: NCT04207541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief motivational interview
Description: Client (who has suboptimal diabetic control with oral anti-diabetic agent) will be advised for insulin initiation with brief motivational interviewing in one session of individual education.
Study: NCT01361204

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Theanine
Description: Taking 4 tablets of theanine two times daily for 16 days
Study: NCT00783484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03716539
Description: PF-03716539 10 mg oral solution, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03716539
Description: PF-03716539 25 mg oral solution, single dose
Study: NCT03196128

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non digital
Description: Communicating with patients via telephone and written appointment letters.
Study: NCT00783484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03716539
Description: PF-03716539 3 mg oral solution, single dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for 3 mg, 10 mg and 25 mg of PF-03716539 (single dose)
Study: NCT01815073

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Attenuated Varicella Vaccine + Live Attenuated JE Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Attenuated Varicella Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: live attenuated JE vaccine
Study: NCT02779543

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit
Description: Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non-dominant hand when prepared for the sleep study by a technician.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jawbone UP
Description: Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non-dominant hand when prepared for the sleep study by a technician.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microsoft Band
Description: Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non-dominant hand when prepared for the sleep study by a technician.
Study: NCT02566278

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper airway collapsibility (Pcrit)
Description: To measure passive Pcrit, patients sleep with a mask over their nose or nose and mouth, and CPAP is applied using a custom made machine that can rapidly change mask pressures in research setting. The idea is that rapid changes in airway pressure produce a clear step change in airflow that will be observed quickly. In contrast, during clinical titrations, the CPAP machines change pressure much more slowly to help promote patient comfort. Passive Pcrit will be measured using both research and clinical equipment in the same patients and the Pcrit result using clinical CPAP titration equipment will be compared to the gold standard: Pcrit measurement done through research equipment that changes CPAP pressure rapidly.
Study: NCT00235079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine 0.5mg BID (\>70Kg) or 0.5 once daily for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT02027740

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: almond
Study: NCT01337973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI-CBT
Description: Six individual psychotherapy sessions during the acute substance use disorder treatment phase integrating motivational interviewing and cognitive behavioral approaches

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI-CBT+CC
Description: Acute phase MI-CBT intervention plus a subsequent 12-week phone based continuing care counseling intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: E-TAU
Description: Enhanced Treatment as Usual
Study: NCT04456452

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ampion
Description: Ampion, administered by intravenous infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of Care
Study: NCT03256045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemosensitivity Assay
Description: Undergo in vitro chemosensitivity testing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Given PO
Study: NCT02298933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: 300 mg single-use vials
Study: NCT02146287

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cycled Light
Description: Cycled light was provided in an 11-hour-on, 11-hour-off pattern. Daylight (240-700 lux) was provided with the incubator cover folded on top of the incubator allowing light in from four sides, or with the bassinet cover off during day hours (0730-1830). With the daylight range of 240-700 lux and limited access to natural light, excessive daylight was prevented.~Continuous near darkness was provided as (5-30 lux) throughout the day except from 0630-0730 and 1830-1930, when lighting levels varied based on nursing care needs at the change of shift. Near-darkness (5-30 lux) was provided by using incubator (totally covered or with the front flap back) and bassinet covers, and dimming individual bedside light during the day (0730-1830) and night hours (1930-0630).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cycled Light
Description: Cycled light was provided in an 11-hour-on, 11-hour-off pattern. Daylight (240-700 lux) was provided with the incubator cover folded on top of the incubator allowing light in from four sides, or with the bassinet cover off during day hours (0730-1830). With the daylight range of 240-700 lux and limited access to natural light, excessive daylight was prevented.~Continuous near darkness was provided as (5-30 lux) throughout the day except from 0630-0730 and 1830-1930, when lighting levels varied based on nursing care needs at the change of shift. Near-darkness (5-30 lux) was provided by using incubator (totally covered or with the front flap back) and bassinet covers, and dimming individual bedside light during the day (0730-1830) and night hours (1930-0630).
Study: NCT02085291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Norepinephrine infusion to titrate MAP to usual level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Norepinephrine infusion to titrate MAP to usual level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crystalloid
Description: Patients received 500 ml crystalloid for fluid challenge within 20 minutes, then a PLR test was performed to predict fluid responsiveness. If the patient was fluid responsive, more 500 ml crystalloids were given until fluid nonresponsive. If the MAP still not achieved the target value, NE was increased to achieve the target one.
Study: NCT00814957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK618334
Description: D3 receptor antagonist
Study: NCT00783484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03716539
Description: PF-03716539 100 mg oral solution, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03716539
Description: PF-03716539 200 mg oral solution, single dose
Study: NCT03609372

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The STOP-HPV Trial 6: Maintenance
Description: In this period, study team support will be withdrawn after previous bundled intervention (including HPV vaccine communication, performance feedback and provider prompts) was given to reduce MOs and increase HPV vaccination rates.
Study: NCT02083458

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheterization of the axillary vein.
Study: NCT01677247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group I (Test) : Glimepiride 4 mg tablet of PT Dexa Medica
Description: In each of the two study periods (separated by a washout of one week) a single dose of test or reference product was administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group II (Reference) : glimepiride (Amaryl) 4 mg tablet of PT Sanofi Aventis
Description: In each of the two study periods (separated by a washout of one week) a single dose of test or reference product was administered.
Study: NCT03742349

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: spartalizumab
Description: LIVI (Liquid in vial) Concentrate for Solution for infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: spartalizumab
Description: LIVI (Liquid in vial) Concentrate for Solution for infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: spartalizumab
Description: LIVI (Liquid in vial) Concentrate for Solution for infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: spartalizumab
Description: LIVI (Liquid in vial) Concentrate for Solution for infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAG525
Description: LAG525 LIVI (Liquid in vial) Concentrate for Solution for infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAG525
Description: LAG525 LIVI (Liquid in vial) Concentrate for Solution for infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAG525
Description: LAG525 LIVI (Liquid in vial) Concentrate for Solution for infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAG525
Description: LAG525 LIVI (Liquid in vial) Concentrate for Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIR178
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capmatinib
Description: Tablet

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCS110
Description: LIVI (Liquid in vial) Concentrate for Solution for infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: canakinumab
Description: LIVI (Liquid in vial) Solution for injection
Study: NCT01409720

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: tailored isometric physical exercise
Study: NCT00493038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (Avelox, BAY12-8039)
Description: Patients will be administered daily a single moxifloxacin 400 mg tablet for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin/Clavulanate
Description: Patient will be administered daily Amoxicilline/Clavulanate 1000 mg tablets every 8 hours for 10 days
Study: NCT03692858

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adductor Canal Block plus IPACK Block
Description: Adductor Canal Block plus IPACK Block using Ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adductor Canal Block
Description: Adductor Canal Block using Ropivacaine
Study: NCT00564811

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Agaricus blazei (Murrill) ss. Heinemann (sun mushroom)
Description: Agaricus blazei powder, 10 grams/day, for 5 months
Study: NCT02904980

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technical Training
Description: Children will watch an instructional video focused on movement related instructions regarding the throwing and catching task.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quiet Eye Training
Description: Children will watch the same video as the TT group but will also receive instructions designed to optimise their quiet eye durations.
Study: NCT01028469

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artelon MTP Spacer
Description: Metatarsophalangeal hemi-implant